Pharmaceutical compositions comprising a pH-dependent component and pH-raising agent
An oral pharmaceutical composition in unit dosage form comprising: (1) a first portion comprising: an active ingredient and a pH-dependent component, and (2) a second portion comprising a pH-raising agent is provided. Methods of administering the composition are also provided.
1. A method of treating pain in a subject in need thereof, comprising administering to the subject an immediate release oral pharmaceutical composition in unit dosage form comprising:
(1) an inner first portion comprising: a first part comprising a core comprising an opioid selected from the group consisting of morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone and codeine, or a pharmaceutically-acceptable salt thereof; and a seal coating, comprising a cellulose resin covering the core; and a second part comprising an acid-sensitive coating comprising a pH-dependent polymer selected from the group consisting of cationic polymers containing a dimethylaminoethyl ammonium group, wherein the acid-sensitive coating is coated on the seal coating of the inner first portion, and releases the opioid at a pH below 4, and wherein the second part substantially covers the first part; and
(2) an outer second portion comprising a pH-raising agent of one or more alkaline compounds selected from the group consisting of sodium bicarbonate, potassium bicarbonate, calcium carbonate, aluminum hydroxide and magnesium hydroxide; and
wherein the second portion substantially covers the first portion; and wherein when two or more unit dosage forms of the oral pharmaceutical composition are administered to a subject within a time period of less than one hour, the amount and/or rate of the opioid released from the first portion is at least about 10% less than the amount and/or rate of the opioid released from the first portion when one unit dosage form is administered.
2. The method of claim 1 , wherein the unit dosage form comprises a tablet.
3. The method of claim 1 , wherein the alkaline compound is present in an amount of about 50 mg to 2,500 mg.
4. The method of claim 1 , wherein the alkaline compound is present in an amount of about 100 mg to 2,000 mg.
5. The method of claim 1 , wherein the alkaline compound is present in an amount of about 250 mg to 1,500 mg.
6. The method of claim 1 , wherein the opioid is selected from the group consisting of oxycodone and morphine, or a mixture thereof or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein when two or more unit dosage forms of said oral composition are administered to a subject within a time period of less than one hour, the amount and/or rate of said opioid released from the first portion is at least about 25% less than the amount and/or rate released from the first portion when one unit dosage form is administered.
8. The method of claim 7 , wherein when two or more unit dosage forms of said oral composition are administered to a subject within a time period of less than one hour, the amount and/or rate of said opioid released from the first portion is at least about 50% less than the amount and/or rate released from the first portion when one unit dosage form is administered.
9. The method of claim 8 , wherein when two or more unit dosage forms of said oral composition are administered to a subject within a time period of less than one hour, the amount and/or rate of said opioid released from the first portion is at least about 75% less than the amount and/or rate released from the first portion when one unit dosage form is administered.
10. The method of claim 1 , wherein the acid-sensitive coating releases the opioid at a pH below 3.
11. The method of claim 1 , wherein the alkaline compound is calcium carbonate or sodium bicarbonate.
12. The method of claim 1 , which oral composition further comprises glidants, lubricants, surfactants, colorants, flavoring agents, and wetting agents.
13. The method of claim 12 , wherein said surfactants in said oral comprise non-ionic, anionic, cationic and amphoteric surfactants.
14. The method of claim 1 , wherein said opioid in said oral composition comprises about 3-400 mg of oxycodone or a pharmaceutically acceptable salt thereof, and about 5-800 mg of morphine or a pharmaceutically acceptable salt thereof per unit dosage form.